Menveo New Ready-to-Use Single Vial Presentation

Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.

Menveo is now available in two presentations:

- Two-vial (requires reconstitution)
 Recommended for ages 2 months and older*
- Single-vial (ready-to-use)
 Recommended for ages 10 years and older
 NOT for use in individuals before their 10th birthday

 To extend existing stocks of MenACWY vaccine products, CDC recommends that health care providers administer specific presentations of age-appropriate vaccines. 			
Ages 2 months through 23 months	Ages 2 years through 9 years	Ages 10 years and older	
Menveo Two-vial (requires reconstitution)	Menveo Two-vial (requires reconstitution) or MenQuadfi (single-dose vial)	Menveo Single-vial (ready-to-use) or MenQuadfi (single-dose vial)	
Menactra is no longer distributed in the U	nited States; available doses will expire in Oc	ctober 2023.	
• Develop a plan to add MenQuadfi to your	inventory if vaccinating children ages 2 years	s through 9 years.	

Important Differences Between Menveo Presentations		
Age Indications	Two-vial (vaccine + vaccine)	Single-vial (ready-to-use)
	Ages 2 months and older	Ages 10 years and older
Presentation Packaging	Supplied as two vials Requires reconstitution • Orange cap vial contains MenA lyophilized conjugate • Gray cap vial contains MenCYW-135 liquid conjugate Each carton contains 10 vials for 5 doses Five vials of Five vials of MenA lyophilized MenCWY135	Supplied as one ready-to-use vial Reconsititution not required • Pink cap vial Each carton contains 10 vials for 10 doses Ten single vials of ready-to-use Menveo
	MenA lyophilized MenCWY135 conjugate component liquid conjugate component	
Storage	Store refrigerated between 36°F and 46°F (2°C and 8°C) Protect from light Do not freeze	
Preparation	 Reconstitution required Only use vaccine vials supplied by manufacturer Mix vaccines vials before administering See Menveo package inse 	Ready-to-use Reconstitution not required to preparation guidance
Dosage/Route	0.5 mL/intramuscular (IM) injection Use immediately after reconstituted	0.5 mL/intramuscular (IM) injection

